Clinical Trial Update: A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD) [Phase 1]

View source ↗

Summary

Phase 1 trial of LY3885125 in participants with dyslipidemia and non-alcoholic fatty liver disease was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• LY3885125

Snippet

Sponsor: Eli Lilly and Company | Conditions: Dyslipidemias, Non-Alcoholic Fatty Liver Disease | Phase 1 | Status: TERMINATED | Results posted: 2026-04-13